BACKGROUND: Phase III trials evaluating the role of secondary cytoreductive surgery (SCS) in recurrent ovarian cancer have pointed to the importance of patient selection. Two studies showed conflicting results regarding the benefit of SCS in BRCA1/2 mutation carriers. Our aim was to evaluate the impact of SCS on recurrent ovarian cancer according to BRCA1/2 status. METHODS: All patients with ovarian carcinoma with platinum-sensitive recurrent disease and tested for BRCA1/2 germline mutations were included. Cox regression and log rank test were used to evaluate the impact of SCS on progression-free survival (PFS) and the influence of BRCA1/2 mutations on the effect of SCS. RESULTS: 127 patients were included, 45.6% were treated with SCS and chemotherapy and 54.3% treated with chemotherapy only. Patients treated with SCS were younger, presented better performance status, had lower CA125, and had a longer platinum-free interval. In multivariate analysis SCS was associated with longer PFS (HR 0.42, 95% CI 0.25-0.72, p = 0.002). BRCA1/2 mutations were found in 35 patients (27.5%), and 11.8% of patients were treated with PARP inhibitors. Although not statistically significant, both BRCA1/2 wild type patients (PFS: 21.6 vs 18.4 months; p = 0.114) and BRCA1/2 mutation carriers (PFS: 23.1 vs 18.2 months, p = 0.193) appeared to derive benefit from SCS. DISCUSSION: The present study suggests a benefit of SCS irrespective of BRCA1/2 status among patients mostly not treated with PARP inhibitor. Further data on post hoc analysis from the phase III trials are warranted to confirm whether BRCA1/2 mutated patients should be selected for SCS.
BACKGROUND: Phase III trials evaluating the role of secondary cytoreductive surgery (SCS) in recurrent ovarian cancer have pointed to the importance of patient selection. Two studies showed conflicting results regarding the benefit of SCS in BRCA1/2 mutation carriers. Our aim was to evaluate the impact of SCS on recurrent ovarian cancer according to BRCA1/2 status. METHODS: All patients with ovarian carcinoma with platinum-sensitive recurrent disease and tested for BRCA1/2 germline mutations were included. Cox regression and log rank test were used to evaluate the impact of SCS on progression-free survival (PFS) and the influence of BRCA1/2 mutations on the effect of SCS. RESULTS: 127 patients were included, 45.6% were treated with SCS and chemotherapy and 54.3% treated with chemotherapy only. Patients treated with SCS were younger, presented better performance status, had lower CA125, and had a longer platinum-free interval. In multivariate analysis SCS was associated with longer PFS (HR 0.42, 95% CI 0.25-0.72, p = 0.002). BRCA1/2 mutations were found in 35 patients (27.5%), and 11.8% of patients were treated with PARP inhibitors. Although not statistically significant, both BRCA1/2 wild type patients (PFS: 21.6 vs 18.4 months; p = 0.114) and BRCA1/2 mutation carriers (PFS: 23.1 vs 18.2 months, p = 0.193) appeared to derive benefit from SCS. DISCUSSION: The present study suggests a benefit of SCS irrespective of BRCA1/2 status among patients mostly not treated with PARP inhibitor. Further data on post hoc analysis from the phase III trials are warranted to confirm whether BRCA1/2 mutated patients should be selected for SCS.
Authors: Barbara M Norquist; Maria I Harrell; Mark F Brady; Tom Walsh; Ming K Lee; Suleyman Gulsuner; Sarah S Bernards; Silvia Casadei; Qian Yi; Robert A Burger; John K Chan; Susan A Davidson; Robert S Mannel; Paul A DiSilvestro; Heather A Lankes; Nilsa C Ramirez; Mary Claire King; Elizabeth M Swisher; Michael J Birrer Journal: JAMA Oncol Date: 2016-04 Impact factor: 31.777
Authors: Hyuna Sung; Rebecca L Siegel; Lindsey A Torre; Jonathan Pearson-Stuttard; Farhad Islami; Stacey A Fedewa; Ann Goding Sauer; Kerem Shuval; Susan M Gapstur; Eric J Jacobs; Edward L Giovannucci; Ahmedin Jemal Journal: CA Cancer J Clin Date: 2018-12-12 Impact factor: 508.702
Authors: Carol Aghajanian; Stephanie V Blank; Barbara A Goff; Patricia L Judson; Michael G Teneriello; Amreen Husain; Mika A Sovak; Jing Yi; Lawrence R Nycum Journal: J Clin Oncol Date: 2012-04-23 Impact factor: 44.544
Authors: Mansoor R Mirza; Bradley J Monk; Jørn Herrstedt; Amit M Oza; Sven Mahner; Andrés Redondo; Michel Fabbro; Jonathan A Ledermann; Domenica Lorusso; Ignace Vergote; Noa E Ben-Baruch; Christian Marth; Radosław Mądry; René D Christensen; Jonathan S Berek; Anne Dørum; Anna V Tinker; Andreas du Bois; Antonio González-Martín; Philippe Follana; Benedict Benigno; Per Rosenberg; Lucy Gilbert; Bobbie J Rimel; Joseph Buscema; John P Balser; Shefali Agarwal; Ursula A Matulonis Journal: N Engl J Med Date: 2016-10-07 Impact factor: 91.245
Authors: F A Raja; N Counsell; N Colombo; J Pfisterer; A du Bois; M K Parmar; I B Vergote; A Gonzalez-Martin; D S Alberts; M Plante; V Torri; J A Ledermann Journal: Ann Oncol Date: 2013-11-04 Impact factor: 32.976
Authors: Robert L Coleman; Nick M Spirtos; Danielle Enserro; Thomas J Herzog; Paul Sabbatini; Deborah K Armstrong; Jae-Weon Kim; Sang-Yoon Park; Byoung-Gie Kim; Joo-Hyun Nam; Keiichi Fujiwara; Joan L Walker; Ann C Casey; Angeles Alvarez Secord; Steve Rubin; John K Chan; Paul DiSilvestro; Susan A Davidson; David E Cohn; Krishnansu S Tewari; Karen Basen-Engquist; Helen Q Huang; Mark F Brady; Robert S Mannel Journal: N Engl J Med Date: 2019-11-14 Impact factor: 91.245
Authors: Robert L Coleman; Mark F Brady; Thomas J Herzog; Paul Sabbatini; Deborah K Armstrong; Joan L Walker; Byoung-Gie Kim; Keiichi Fujiwara; Krishnansu S Tewari; David M O'Malley; Susan A Davidson; Stephen C Rubin; Paul DiSilvestro; Karen Basen-Engquist; Helen Huang; John K Chan; Nick M Spirtos; Raheela Ashfaq; Robert S Mannel Journal: Lancet Oncol Date: 2017-04-21 Impact factor: 41.316
Authors: Robert L Coleman; Amit M Oza; Domenica Lorusso; Carol Aghajanian; Ana Oaknin; Andrew Dean; Nicoletta Colombo; Johanne I Weberpals; Andrew Clamp; Giovanni Scambia; Alexandra Leary; Robert W Holloway; Margarita Amenedo Gancedo; Peter C Fong; Jeffrey C Goh; David M O'Malley; Deborah K Armstrong; Jesus Garcia-Donas; Elizabeth M Swisher; Anne Floquet; Gottfried E Konecny; Iain A McNeish; Clare L Scott; Terri Cameron; Lara Maloney; Jeff Isaacson; Sandra Goble; Caroline Grace; Thomas C Harding; Mitch Raponi; James Sun; Kevin K Lin; Heidi Giordano; Jonathan A Ledermann Journal: Lancet Date: 2017-09-12 Impact factor: 79.321
Authors: Jonathan Ledermann; Philipp Harter; Charlie Gourley; Michael Friedlander; Ignace Vergote; Gordon Rustin; Clare L Scott; Werner Meier; Ronnie Shapira-Frommer; Tamar Safra; Daniela Matei; Anitra Fielding; Stuart Spencer; Brian Dougherty; Maria Orr; Darren Hodgson; J Carl Barrett; Ursula Matulonis Journal: Lancet Oncol Date: 2014-05-31 Impact factor: 41.316
Authors: Rafaela Pirolli; Viviane Teixeira Loiola de Alencar; Felipe Leonardo Estati; Adriana Regina Gonçalves Ribeiro; Daniella Yumi Tsuji Honda; Mariana de Oliveira; Joao Paulo da Silveira Nogueira Lima; Elizabeth Santana Dos Santos; Andrea Paiva Gadelha Guimarães; Glauco Baiocchi; Alexandre André Balieiro Anastácio da Costa Journal: BMC Cancer Date: 2021-05-08 Impact factor: 4.430